DAEWOONG PHARMACEUTICAL
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug 2022-07-20 21:00
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis 2022-06-24 21:00
Daewoong Pharmaceutical announced first-quarter 2022 results 2022-05-05 21:00
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative 2022-04-13 08:00
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/ 2022-04-12 15:34
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines 2022-03-29 09:00
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy 2022-02-25 22:00
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer 2022-02-21 22:00
Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development 2022-02-21 22:00
Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug 2022-01-25 22:00
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update 2022-01-20 22:00
Daewoong's "Leaps and Bounds" Q3 Performance, Exceeds KRW 20B in Operating Income for Three Consecutive Quarters 2021-11-02 21:00
HanAll Biopharma Reports Third Quarter 2021 Results 2021-10-28 21:00
CGBIO to introduce AI-empowered robotic intervention device, with clinical trials 2021-09-27 21:00
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics 2021-08-19 21:00
HanAll Biopharma Reports Second Quarter 2021 Results 2021-07-29 18:44
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial 2021-07-29 18:00
Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes 2021-06-01 21:00
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test 2021-05-27 21:00
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis (IPF) shows promising result in early stage clinical test 2021-05-24 16:59
1 2 3